Tags

Type your tag names separated by a space and hit enter

Maintenance of the ratio of bioactive to immunoreactive follicle-stimulating hormone in normal men during chronic luteinizing hormone-releasing hormone agonist administration.
J Clin Endocrinol Metab. 1988 May; 66(5):1005-9.JC

Abstract

Chronic administration of LHRH agonist analogs to humans reduces gonadal function through pituitary desensitization. Serum immunoreactive gonadotropin levels are modestly reduced, whereas serum bioactive LH levels are drastically suppressed. The effects on bioactive FSH levels, however, are not known. In this study, serum bioactive FSH was measured using an in vitro granulosa cell aromatase bioassay in four normal men given a LHRH agonist, [D-Trp6,Pro9-NEt]LHRH (LHRHA; 500 micrograms/day for 16 weeks), by sc infusion and testosterone enanthate (TE; 100 mg, im every 2 weeks) and in five men given 500 micrograms/day LHRHA by daily sc injection for 20 weeks and TE (100 mg every 2 weeks) from weeks 10 through 20. During the first study, serum immunoreactive FSH levels (IR-FSH) decreased by 56.5 +/- 4.8% (+/- SEM), and serum bioactive FSH (Bio-FSH) level decreased by 57.6 +/- 6.4%. The ratio of Bio-FSH to IR-FSH did not change. During the second study, both serum IR-FSH and Bio-FSH levels followed a triphasic pattern, decreasing slightly but not significantly immediately after initiation of LHRHA administration, progressively increasing to a peak (P less than 0.5 vs, baseline) at week 10, and then, after addition of TE to this regimen, decreasing slightly again. The Bio-FSH to IR-FSH ratio, as in the first study, did not change. When serum obtained at week 10 during the second study, just before initiation of TE, was chromatographed on a Sephadex G-100 column, IR-LH eluted in two distinct peaks, while IR-FSH eluted as a single peak. These results demonstrate that in normal men chronic LHRHA administration alone for up to 10 weeks or LHRHA plus TE for up to 16 weeks does not alter the qualitative characteristics of secreted FSH, since there was no dissociation between serum IR- and Bio-FSH levels.

Authors+Show Affiliations

Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

2834409

Citation

Pavlou, S N., et al. "Maintenance of the Ratio of Bioactive to Immunoreactive Follicle-stimulating Hormone in Normal Men During Chronic Luteinizing Hormone-releasing Hormone Agonist Administration." The Journal of Clinical Endocrinology and Metabolism, vol. 66, no. 5, 1988, pp. 1005-9.
Pavlou SN, Dahl KD, Wakefield G, et al. Maintenance of the ratio of bioactive to immunoreactive follicle-stimulating hormone in normal men during chronic luteinizing hormone-releasing hormone agonist administration. J Clin Endocrinol Metab. 1988;66(5):1005-9.
Pavlou, S. N., Dahl, K. D., Wakefield, G., Rivier, J., Vale, W., Hsueh, A. J., & Lindner, J. (1988). Maintenance of the ratio of bioactive to immunoreactive follicle-stimulating hormone in normal men during chronic luteinizing hormone-releasing hormone agonist administration. The Journal of Clinical Endocrinology and Metabolism, 66(5), 1005-9.
Pavlou SN, et al. Maintenance of the Ratio of Bioactive to Immunoreactive Follicle-stimulating Hormone in Normal Men During Chronic Luteinizing Hormone-releasing Hormone Agonist Administration. J Clin Endocrinol Metab. 1988;66(5):1005-9. PubMed PMID: 2834409.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Maintenance of the ratio of bioactive to immunoreactive follicle-stimulating hormone in normal men during chronic luteinizing hormone-releasing hormone agonist administration. AU - Pavlou,S N, AU - Dahl,K D, AU - Wakefield,G, AU - Rivier,J, AU - Vale,W, AU - Hsueh,A J, AU - Lindner,J, PY - 1988/5/1/pubmed PY - 1988/5/1/medline PY - 1988/5/1/entrez SP - 1005 EP - 9 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 66 IS - 5 N2 - Chronic administration of LHRH agonist analogs to humans reduces gonadal function through pituitary desensitization. Serum immunoreactive gonadotropin levels are modestly reduced, whereas serum bioactive LH levels are drastically suppressed. The effects on bioactive FSH levels, however, are not known. In this study, serum bioactive FSH was measured using an in vitro granulosa cell aromatase bioassay in four normal men given a LHRH agonist, [D-Trp6,Pro9-NEt]LHRH (LHRHA; 500 micrograms/day for 16 weeks), by sc infusion and testosterone enanthate (TE; 100 mg, im every 2 weeks) and in five men given 500 micrograms/day LHRHA by daily sc injection for 20 weeks and TE (100 mg every 2 weeks) from weeks 10 through 20. During the first study, serum immunoreactive FSH levels (IR-FSH) decreased by 56.5 +/- 4.8% (+/- SEM), and serum bioactive FSH (Bio-FSH) level decreased by 57.6 +/- 6.4%. The ratio of Bio-FSH to IR-FSH did not change. During the second study, both serum IR-FSH and Bio-FSH levels followed a triphasic pattern, decreasing slightly but not significantly immediately after initiation of LHRHA administration, progressively increasing to a peak (P less than 0.5 vs, baseline) at week 10, and then, after addition of TE to this regimen, decreasing slightly again. The Bio-FSH to IR-FSH ratio, as in the first study, did not change. When serum obtained at week 10 during the second study, just before initiation of TE, was chromatographed on a Sephadex G-100 column, IR-LH eluted in two distinct peaks, while IR-FSH eluted as a single peak. These results demonstrate that in normal men chronic LHRHA administration alone for up to 10 weeks or LHRHA plus TE for up to 16 weeks does not alter the qualitative characteristics of secreted FSH, since there was no dissociation between serum IR- and Bio-FSH levels. SN - 0021-972X UR - https://www.unboundmedicine.com/medline/citation/2834409/Maintenance_of_the_ratio_of_bioactive_to_immunoreactive_follicle_stimulating_hormone_in_normal_men_during_chronic_luteinizing_hormone_releasing_hormone_agonist_administration_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jcem-66-5-1005 DB - PRIME DP - Unbound Medicine ER -